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Abstract
Intracardiac defibrillator plays a pivotal role in preventing sudden cardiac death; however, 
inappropriate shock delivery remains an important source of morbidity and mortality. 
Advancements in device technology along with various shock reduction strategies play 
a key role in reducing inappropriate and unnecessary shocks. Anti-tachycardia pacing 
(ATP) is the first-line therapy prior to shock delivery. Several trials have validated the effi-
cacy of ATP for both slow and fast ventricular tachycardia without significant increase in 
occurrence of arrhythmia-related syncope. In addition, trials also support that therapy for 
non-sustained tachycardia can be prevented by higher programmed zones and prolonged 
intervals to detect without higher risk of syncope. With this perspective, authors employ a 
customized programming for both primary and secondary prevention to reduce inappro-
priate therapies or unnecessary therapies, in particular, progression to shock but allow for 
spontaneous termination at slower ventricular tachycardia rates. The programming was 
instituted at the time of device implantation or at follow up.
Keywords: intracardiac defibrillator, anti-tachycardia pacing, inappropriate therapies, 
shock, customized programming, ICD programming, ICD therapies, reducing ICD 
therapies, ICD templates
1. Introduction
Implantable cardioverter-defibrillator (ICD) remains the main therapeutic option in reduc-
ing sudden cardiac death (SCD). Several randomized trials and registries have shown that 
ICD extends survival in patients with severe left ventricular function and mild-to-moderate 
heart failure [1–4]. The shocks delivered whether appropriate, inappropriate or unnecessary 
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remain an important source of mortality and morbidity from proarrhythmic potential, heart 
failure, painful delivery of shock causing significant anxiety, depression and post-traumatic 
stress disorder [5–11].
Inappropriate ICD shocks are those delivered for a condition other than true ventricular 
arrhythmias, which most commonly include supraventricular arrhythmias with rapid rates, 
mechanical failure of ICD lead/system like lead conductor fracture resulting in noise detec-
tion and non-mechanical issues such as T-wave over sensing resulting in double-counting 
[3]. Unnecessary or potentially avoidable shocks are those where the ventricular tachycardia 
(VT) was to terminate spontaneously or could have been interrupted by appropriately timed 
pacing stimuli.
Table 1 lists the major clinical trials and registries reporting the incidence of inappropriate 
shocks. We review some of the trials here.
The anti-arrhythmics versus implantable defibrillators (AVID) was a multi-centre trial which 
patients were randomized to receive ICD or anti-arrhythmic drug therapy; 492 patients were 
randomized to receive an ICD over a follow-up period of 22 ± 12 months. Inappropriate 
shocks in this cohort were due to supraventricular tachycardia in 18% and 3% were due to 
ICD malfunction or inappropriate sensing [12].
The Pain FREE Rx II trial was a prospective randomized control trial consisting of 634 patients 
with a mean follow up of 11 ± 3 months. All patients received ICDs and were randomized 
to anti-tachycardia pacing versus shock only programming [13]. There were 4230 spontane-
ous episodes retrieved from all implanted ICDs, 1837 had complete electrogram data and 
were included in the analysis. Of these, 491 episodes (27%) were determined to be inappro-
priately detected supraventricular tachycardia (SVT), and 4 (0.2%) were non-physiological 
artifact. Sweeny et al. performed a subgroup analysis of the PainFree trial and showed that 
the proportion of true ventricular detections that resulted in shocks was similar between pri-
mary and secondary prevention groups (40% versus 32%, respectively) [14]. The proportion 
of inappropriate ventricular detections due to SVT that resulted in shocks was also similar 
between primary and secondary prevention groups (44% versus 42%, respectively).
MIRACLE ICD was a prospective, randomized double-blind trial of 978 patients with a mean 
10-month follow-up [15]. This trial evaluated the safety and efficacy of cardiac resynchroniza-
tion combined defibrillator therapy (CRT-D) versus ICD only therapy in both primary and 
secondary prevention patients. The reported incidence of inappropriate shocks was 30% in 
primary prevention patients and 14% in secondary prevention patients.
In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II), inappropriate 
shocks constituted 31.2% (184/590) of the total shock episodes [16]. The most common trig-
gers were atrial fibrillation (44%) and supraventricular tachycardia (36%) with improper 
discrimination by the ICD device, followed by abnormal sensing (20%). The majority of 
inappropriate ICD therapy episodes were delivered for rhythms below or equal to 200 bpm; 
the mean ventricular rate triggering inappropriate shock for atrial fibrillation (AF) or SVT 
was 174 ± 22 bpm. Patients with inappropriate ICD shocks showed a significantly higher 
mortality during the follow-up (HR = 2.29, 95% CI: 1.11–4.71, p = 0.02) than patients with 
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Clinical trial AVID [12] PainFREE [13] MIRACLE ICD 
[15]
MADIT II [16] SCD-Heft [17] ALTITUDE ICD 
[18]
ALTITUDE 
CRT-D [18]
Leidin [19]
Patient no. 449 582 978 719 811 39,396 29,904 1544
Follow up, months 22 11 10 20 46 28 28 41
Single/dual Single/dual Single/dual Single/dual Single/dual Single Single/dual Single/dual Single/dual
Primary/secondary Secondary Primary/
secondary
Primary/
secondary
Primary Primary Primary/
secondary
Primary/
secondary
Primary/
secondary
Inappropriate 
Rx, %
21 15 14–30* 12 17 16 17 18
Inappropriate Rx, 
(HR, 95% CI, p)
n.a n.a n.a 2.29 (1.11–4.71) 
0.02
1.98 (1.29–3.05) 
0.002
1.84 (1.30–2.61) 1.60 (1.15–2.23) 1.60 (1.10–2.30) 
p = 0.01
Appropriate Rx, % 68 33 23–31** 21 23 23 23 n.a
Appropriate Rx, 
(HR, 95% CI, p)
n.a n.a n.a 3.36 (2.04–5.55) 
<0.01
5.68 (3.97–8.12) 
<0.001
2.05 (1.55–2.71) 2.51 (2.01–3.14) 1.60 (1.20–2.10) 
<0.01
ATP (yes/no) Yes Yes Yes Yes No Yes Yes Yes
Outcome measure n.a n.a n.a Mortality Mortality Mortality Mortality Mortality
*14% in secondary prevention and 30% in primary prevention.
**23% in primary prevention and 31% in secondary prevention.
Table 1. List of ICD clinical trials and registries with frequency of appropriate and inappropriate therapy and outcome.
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appropriate ICD shocks (HR = 3.36, 95% CI: 2.04–5.55, p < 0.01). This demonstrated that all 
shocks, although demonstrated to save lives, also have a detrimental effect and lead to heart 
failure deterioration and eventual mortality.
Similar data could be extrapolated from the sudden cardiac death in heart failure trial (SCD-
HeFT) [17]. In this trial, 2521 patients with primary prevention indication and with mild-to-
moderate heart failure were randomized in equal proportions to receive placebo, amiodarone 
or a single-chamber ICD programmed to shock-only mode. Follow-up was for an average 
of 46 months. In 811 patients assigned to the ICD arm, the rate of inappropriate shocks was 
17% as compared to 22.4% appropriate shocks during a 46-month follow-up. Patients with an 
inappropriate ICD therapy had a twofold increase in the risk of all-cause mortality (HR = 1.98, 
95% CI: 1.29–3.05, p = 0.002).
The results from the randomized trials were confirmed in larger registries. The ALTura Impact 
on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design 
(ALTITUDE) registry involved 39,396 ICD patients and 29,904 patients implanted CRTDs. 
Patients were implanted for both primary and secondary indications [18]. The 1-year inci-
dence of inappropriate shocks was 8% and 6% and at 5 years increased to 16% and 17% for 
ICD and CRT-D patients, respectively. The two most common reasons for shock were atrial 
flutter/atrial fibrillation and sinus tachycardia or supraventricular arrhythmia. Inappropriate 
shock was due to noise, artifact or over sensing in 3% of the episodes.
The Leiden group published a large scale study in 1544 ICD patients and reported an 18% inci-
dence of inappropriate ICD therapy over 41 months of follow-up. This study also confirmed 
the increased risk of death for both inappropriate and appropriate ICD therapy (HR1.60 for 
both, p = 0.01 for inappropriate; p < 0.01 for appropriate ICD therapy) [19].
2. Possible mechanism of increased risk of death with ICD shocks
It may be hypothesized that there is a direct mechanical or hemodynamic effect of the inap-
propriate ICD therapies themselves or that some of the inappropriate ICD therapies lead to 
fatal pro-arrhythmia due to an increase in sympathetic discharge, which in turn leads to rate-
related changes in ventricular refractoriness and worsened myocardial ischemia [20].
It is likely that it is not the inappropriate shock per se that is detrimental, but the sequelae that 
hastens the adverse clinical outcome.
It has been suggested that high shock fields are associated with changes in electrophysiologi-
cal properties of the heart and can be the primary source of activation wave fronts that may 
give rise to idioventricular rhythms after the shock and perhaps may even perpetuate ven-
tricular fibrillation [21]. The cellular injury from intra-cardiac shock delivery whether it be 
appropriate or not is reflected in a rise in cardiac troponin I [22]. Though the result may be a 
rescue from acute ventricular arrhythmia, studies have shown a relationship with increased 
mortality and morbidity from progression to heart failure as a consequence of the myocardial 
stunning [5–11].
Interpreting Cardiac Electrograms - From Skin to Endocardium122
Minimizing the need for shock delivery overall will, therefore, ultimately prevent the down-
stream complications.
3. Shock reducing strategies
There have been several technological advancements to improve ICD therapy delivery and 
to avoid inappropriate and unnecessary ICD therapies. The shock reduction programming 
strategies may be divided into the following categories:
• Optimizing ventricular tachyarrhythmia discrimination by applying advanced detection 
algorithms in all therapy zones.
• Delaying onset of anti-tachycardia therapies either by prolonged detection intervals or set-
ting higher tachycardia detection limits.
• Using anti-tachycardia pacing (ATP) as first-line therapy whenever possible prior to shock 
delivery.
4. Clinical evidence and the rationale to support ATP therapy
Monomorphic VT can be interrupted when an appropriately timed pacing stimulus is deliv-
ered into the excitable gap of a re-entrant circuit where a collision with the orthodromic wave 
front results in termination of the tachycardia.
An alternative explanation is that the paced stimuli result in myocardial depolarization dur-
ing the relative refractory period. This pre-excites the preceding wave front, thereby altering 
myocardial excitability and extinguishing the propagation re-entrant VT [23].
The duration of the excitable gap and the conduction time from the pacing stimulus site to 
the re-entrant circuit are the main factors influencing penetration of the excitable gap and 
termination of the arrhythmia [24].
Ventricular conduction time is influenced by anatomic and functional barriers as well as the 
influence of the sympathetic nervous system [25]. The efficacy of the ATP is improved with 
adequate beta blockade and is not adversely influenced by other anti-arrhythmic drugs as is 
the case with defibrillation thresholds [26].
5. Customized programming
Several trials have validated the efficacy of ATP in terminating slower cycle length of VT.
The Pain FREE Rx II trial was the first trial that extended the use of ATP for fast VT (FVT) 
with heart rates of 188–250 beats/min. This study also used longer intervals to detect VT as 
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compared to the previous conventional programming (Figure 1) [13, 27]. The result was that 
73% of FVT episodes were successfully terminated by the ATP.
It also showed that FVT made up 76% of all ventricular arrhythmias that would have conven-
tionally been treated by shock alone according to conventional ICD programming.
Acceleration of FVT occurred in patients programmed to receive ATP as well as those in the 
shock only group: 4/273 monomorphic VT episodes (2%) in the ATP arm versus 2/145 (1%) 
in the shock arm. There were also three episodes of syncope during treatment for FVT (ATP, 
n = 2; shock, n = 1). This study, therefore, established the safety and efficacy of ATP for both 
slow and FVT as first-line therapy in ICDs with a non-significant occurrence or difference in 
arrhythmia-related syncope in either therapy arm.
The next stage in the evolution of device therapy programming was to defer treatment 
(VT detection) till absolutely necessary. In this regard, the Primary Prevention Parameters 
Evaluation (PREPARE) trial (Figure 2) [28] evaluated a prolonged detection interval duration 
of 30/40 ventricular beats and an increased tachycardia detection interval (TDI) of 182 beats/
min. Supraventricular detection discrimination algorithms and ATP were also optimized 
in this programming strategy. Arrhythmic syncope was only 1.6% in the test programming 
strategy. All-cause mortality in the PREPARE study group was also relatively low (Kaplan-
Meier estimated 12-month mortality of 4.9%). Thus, the overall safety behind the rationale of 
this programming was acceptable.
Figure 1. Programming strategy of experimental and control arm in Pain FREE Rx II trial.
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The multicenter automatic defibrillator implantation trial–reduce inappropriate therapy 
(MADIT-RIT) trial compared three arms: (a) conventional ICD detection of VT with a (b) 
prolonged detection interval and (c) a higher tachycardia detection interval (Figure 3) [29].
The results validated the safety of both the active test arms. There was a 79% reduction in 
the incidence of therapy in the high-rate group than in the conventional therapy group and 
delayed therapy (longer detection interval programming) was associated with a 76% reduc-
tion in overall therapy delivery. Mortality was reduced by 55% in the high-rate group (p = 
0.01) and by 44% in the delayed-therapy group (p = 0.06). Despite withholding therapies till 
absolutely needed, there was a mortality improvement in these active programming options.
The incidence of syncope was similar between the groups and was not clinically significant: 
high rate strategy and delayed therapy versus conventional arm (p = 0.39, p = 0.80).
Both delayed therapy and higher rate programming were shown to be safe and efficacious.
Figure 2. Programming strategy of experimental arm in PREPARE trial with controls from EMPIRIC and MIRACLE 
ICD patients.
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The ADVANCE III (Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD 
Patients III) [30] reinforced the findings from the MADIT-RIT trial and included both primary 
and secondary prevention patients, with or without atrial fibrillation, in whom single-, dual- 
and triple-chamber ICD were implanted [30]. Thus, this randomized control trial applied an 
extended detection interval strategy to a heterogeneous cohort of ICD recipients and more 
likely to resemble a real world setting (Figure 4).
This delayed arrhythmia detection strategy resulted in a reduction in the combined end point 
of all ICD therapies (ATPs and shocks) with 346 delivered therapies (42 therapies per 100 
person-years) in test group (extended-detection interval) versus 557 in the control group 
(standard-detection interval) (67 therapies per 100 person-years); p < 0.001.
The incidence of arrhythmic syncope was low in both groups and did not differ significantly 
with rates of 3.1 versus 1.9 per 100 patient-years (p = 0.220 in the extended detection and 
standard detection groups, respectively). The syncopal episodes were not associated with any 
additional adverse outcomes. The mortality rates were 5.5 versus 6.3 per 100 patient-years 
(p = 0.50) in extended detection and standard detection, respectively. Both were low and com-
parable to what was reported in the MADIT-RIT trial.
Similarly the PROVIDE (Programming Implantable Cardioverter Defibrillators in Patients 
with Primary Prevention Indication to Prolong Time to First Shock) trial was a program-
ming strategy with combination of higher detection rates, prolonged detection intervals, opti-
mized SVT discriminators and empiric ATP therapy compared to conventional parameters in 
patients receiving ICDs for primary prevention (Figure 5) [31]. The primary end point was 
time to first shock delivery. The median time to first shock was significantly longer at 13.1 
months in experimental group versus 7.8 months in the control group. In addition, the 2-year 
shock rate was 12.4% in the experimental group compared to 19.4% in the control group. An 
overall reduction in both appropriate and inappropriate shock and ATP was observed. The 
decrease in ICD therapies was associated with a 30% relative reduction in all-cause mortality.
The incidence of arrhythmic syncope was not significantly different between the two groups 
with overall incidence of 1.7% over 2 years of follow-up.
Figure 3. Programming strategy of MADIT-RIT patients.
Interpreting Cardiac Electrograms - From Skin to Endocardium126
With this perspective, we can summarize the overall current trends in ICD programming:
1. Higher zone thresholds
2. Prolonged detection duration or detection intervals
3. Use of advanced discriminators in all zones
4. Use of tiered therapies with ATP as first line therapy before shock delivery.
The aim of these strategies is to reduce inappropriate therapies (ITS) particularly progression 
to shock and not to over treat ventricular arrhythmias but to allow for spontaneous termina-
tion at ventricular rates that are safe to do so.
Figure 4. Programming strategy in ADVANCE III trial.
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There has been no data to suggest that implanting dual chamber ICDs is more advantageous in 
ventricular arrhythmia over single chamber devices in any of the studies we have mentioned. 
However, there are some practical reasons where one may choose to implant an atrial lead as 
well to enhance discrimination algorithms [32].
• In patients who require pacing for bradycardia, AV sequential pacing would be preferable.
• In patients with bradycardia-induced or pause-dependent ventricular tachyarrhythmia 
(such as patients with long QT syndrome and torsades de pointes).
• In patients with documented history of paroxysmal atrial arrhythmias (atrial EGMS will 
help distinguish the chamber of onset of the tachycardia).
Figure 5. Programming strategy of experimental arm in PROVIDE trial with control population from the PROVE trial.
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• In patients with hypertrophic cardiomyopathy as they are prone to atrial arrhythmias but 
may also require pacing.
With this in mind, we employ the following customized ICD programming (Tables 2 and 3) 
for both primary and secondary prevention of SCD in our patients.
Medtronic St. Jude medical Biotronik Boston scientific Sorin
VF (VF + FVT) 
rate in bpm
230–240 250 250 220 200–240
NID 30 30 12/16 2.5 s initial 
duration
6 cycles
Therapy ATP during 
charge
ATP during 
charge
ATP: Burst 1 ATP: Burst 1 ATP: Burst 1
Shock × 6 Shock × 6 Shock × 6 Shock × 6 Shock × 6
VT2 (FVT via 
VF) CL
250 200 200 200 200
NID 30 30 28 (RD-14) 10 s initial 
duration
6 cycles
Therapy ATP: Burst 1 ATP: Burst 1 ATP: Burst 1 ATP: Burst 1 ATP: Burst 1
Shock × 5 Shocks × 4 Shocks × 5 Shocks × 5 Shocks × 5
VT1 CL in bpm 171 171 171 170 170
NID 28 30 30 (RD-16) 30 s initial 
duration
12 cycles
Therapy ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
Shocks × 4 Shocks × 3 Shocks × 4 Shocks × 4 Shocks × 4
Monitor CL in 
bpm
150 150
NID 32 12 cycles
Therapy None None
ATP programming
Medtronic St. Jude Biotronik Boston Sorin
Burst 1 8/88/3 8/88/3 8/85/3 8/88/3 8/85/3
Burst 2 8/84/3 8/84/3 8/85/3 8/84/3 8/85/3
Ramp 8/91 8/91 8/90 8/91 8/90
Time out: OFF (Boston Scientific); ATP smart mode: OFF (Medtronic); progressive therapy: ON (Medtronic >2 active 
zone); ATP optimization: ON (Biotronik); upper rate ATP cut off 260 beats/min (St. Jude); readaptive: ON (St. Jude); 
Ramp OFF unless specified.
NID: Numbers of interval to detect.
Table 2. Suggested customized ICD programming strategy proposed by the authors for primary prevention.
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The programming is instituted at the time of device implantation and refined (if needed) at 
follow-up in the device clinic.
The programming covers all manufacturers’ ICDs that we commonly implant. The custom 
sets are preloaded onto our programmers, thus minimizing the need for tedious reprogram-
ming and only need to be refined if the case warrants this.
Medtronic St. Jude medical Biotronik Boston Scientific Sorin
VF (VF + FVT) 
rate in bpm
200 250 250 220 200–240
NID 30 30 12/16 2.5 s initial 
duration
6 cycles
Therapy ATP during 
charge
ATP during 
charge
ATP: 1 Burst ATP: Burst 1
Shock × 6 Shock × 6 Shock × 6 Shock × 6 Shock × 6
VT2 (FVT via VF) 
rate in bpm
250 200 200 200 200
NID 30 30 28 (RD-14) 10 s initial 
duration
6 cycles
Therapy ATP: Burst 1 ATP: Burst 1 ATP: 1 Burst ATP: Burst 1 ATP: Burst 1
Shock × 5 Shocks × 4 Shocks × 5 Shocks × 5 Shocks × 5
VT1 rate in bpm 171/VT-20 171/VT-20 171/VT-20 170/VT-20 170/VT-20
NID 28 30 30 (RD-16) 30 s initial 
duration
12 cycles
Therapy ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
ATP: Burst 1 + 
Burst 2
Shocks ×4 Shocks ×3 Shocks ×4 Shocks ×4 Shocks ×4
Monitor rate in 
bpm
150/VT-30 150/VT-30
NID 32 12 cycles
Therapy None None
ATP programming
Medtronic St. Jude Biotronik Boston Sorin
Burst 1 8/88/3 8/88/3 8/85/3 8/88/3 8/85/3
Burst 2 8/84/3 8/84/3 8/85/3 8/84/3 8/85/3
Ramp 8/91 8/91 8/90 8/91 8/90
Time out: OFF (Boston Scientific); ATP smart mode: OFF (Medtronic); progressive therapy: ON (Medtronic >2 active 
zone); ATP optimization: ON (Biotronik); upper rate ATP cut off 260 beats/min (St. Jude); readaptive: ON (St. Jude); 
Ramp OFF unless specified.
Table 3. Suggested customized ICD programming strategy proposed by the authors for secondary prevention.
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In doing so, the work flow both in the implant suite and at the follow-up device visit is facili-
tated and the programming can be delegated to our allied professional nurses and cardiac 
technicians.
6. Conclusion
With the complexity and sophistication of ICD algorithms, the programming of these cardiac 
devices has become a discipline and challenge in its own right. We have found that it has been 
difficult to maintain predictability and consistency in the programming of ICDs in our cen-
tre, hence a need arose to develop a programming template. This was derived from current 
trends in programming and is mentioned here in an extensive review of the literature. There 
is an obvious limitation in which each of the studies has been manufacturer specific. We have 
tried to identify the principles on which the programming was based and then developed a 
generic template. This was however still done with due consultation with the manufacturers 
to ensure applicability and safety with the specific algorithms. There have also been very few 
studies that deal with programming of secondary prevention of ICDs. We have strived to 
maintain a compromise between all manufacturers to reach a consensus on programming for 
primary prevention of ICDs.
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